## Form to function: current and future roles for atheroscl development

Nature Reviews Drug Discovery 7, 517-529 DOI: 10.1038/nrd2588

Citation Report

#	Article	IF	CITATIONS
1	"Feeling the RAGE―in the Atherosclerotic Vessel Wall. Circulation: Cardiovascular Imaging, 2008, 1, 178-179.	1.3	1
2	Morphology: Bodies, Genes, Journals. Croatian Medical Journal, 2009, 50, 1-3.	0.2	3
3	First head-to-head comparison of effective radiation dose from low-dose 64-slice CT with prospective ECG-triggering versus invasive coronary angiography. Heart, 2009, 95, 1656-1661.	1.2	89
4	Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovascular Research, 2009, 83, 425-435.	1.8	28
5	Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers. Circulation: Cardiovascular Imaging, 2009, 2, 107-115.	1.3	227
6	Inflammation Imaging in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1009-1016.	1.1	117
7	Lipid raft redox signaling platforms in vascular dysfunction: Features and mechanisms. Current Atherosclerosis Reports, 2009, 11, 220-226.	2.0	17
8	INTRODUCTION. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 84-87.	0.9	1
9	What is the future for drug development in atherosclerosis and dyslipidaemia?. Expert Opinion on Drug Discovery, 2009, 4, 1-3.	2.5	6
10	Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function. Journal of the American College of Cardiology, 2009, 54, 1787-1794.	1.2	237
11	Pathophysiology of coronary artery disease: the case for multiparametric imaging. Expert Review of Cardiovascular Therapy, 2009, 7, 299-310.	0.6	1
12	Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 983-991.	1.1	92
13	Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opinion on Investigational Drugs, 2009, 18, 1425-1430.	1.9	16
14	Serial Intravascular Ultrasound Assessment of Atherosclerosis Progression and Regression State-of-the-Art and Limitations. Circulation Journal, 2009, 73, 1557-1560.	0.7	22
15	The ATHEROMA Study: Rapid Anti-inflammatory Effects of High-Dose Statin Pharmacotherapy Illuminated by Molecular MRI. Current Cardiovascular Imaging Reports, 2010, 3, 1-3.	0.4	0
16	The pathogenesis of atherosclerosis. Medicine, 2010, 38, 397-402.	0.2	26
18	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Circulation, 2010, 122, e584-636.	1.6	1,009
19	Biomarkers of Vulnerable Atheromatous Plaques. Advances in Clinical Chemistry, 2010, 50, 1-22.	1.8	16

ARTICLE IF CITATIONS # Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in 20 2.3 144 Experimental Atherosclerosis. Molecular Pharmaceutics, 2010, 7, 2020-2029. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of 1.2 1,150 the American College of Cardiology, 2010, 56, e50-e103. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using 22 0.4 98 microparticles of iron oxide. Atherosclerosis, 2010, 209, 18-27. Ischemic heart disease: Comprehensive evaluation by cardiovascular magnetic resonance. American Heart Journal, 2011, 162, 16-30. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nature 24 21.5 341 Reviews Drug Discovery, 2011, 10, 835-852. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. International Journal of Nanomedicine, 2011, 6, 1279. 3.3 Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. Journal of 26 4.8 65 Controlled Release, 2011, 155, 211-217. Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: Relationships with coronary disease severity. 1.6 10 Journal of Cardiovascular Magnetic Resonance, 2011, 13, 61. A fluorescence lifetime spectroscopy study of matrix metalloproteinases  $\hat{e}_2$  and  $\hat{a}_{9}$  in human 28 1.1 10 atherosclerotic plaque. Journal of Biophotonics, 2011, 4, 650-658. Macrophage Detection in Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 29 1.1 31, 723-724. Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque 30 2.3 33 dimensions and composition: an update. European Journal of Echocardiography, 2011, 12, 313-321. Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints. 1.2 24 Heart, 2011, 97, 1286-1292. Absolute Quantification of Myocardial Perfusion. Circulation: Cardiovascular Imaging, 2011, 4, 32 1.3 0 607-609. Atherosclerosis Drug Development in Jeopardy: The Need for Predictive Biomarkers of Treatment 5.8 Response, Science, Translational Medicine, 2011, 3, 72cm6, and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:math mathvariant="bold-italic">î±</mml:mi></mml:mi></mml:mi></mml:mi></mml:mi></mml:msub><mml:miml:mi></mml:mi></mml:msub></mml:msub></mml:msub></mml:miml:mi></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub></mml:msub>< 34 1.3 27 mathvariant="bold">3</mml:mn></mml:msub></mml:mrow></mml:math> Integrin. International lourna Novel anti-inflammatory strategies in atherosclerosis. Current Opinion in Lipidology, 2012, 23, 532-539. 1.2 39 Integrin-Mediated Drug Delivery in Cancer and Cardiovascular Diseases with Peptide-Functionalized 36 1.2 34 Nanoparticles. Current Medicinal Chemistry, 2012, 19, 3128-3151. Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging. Methods in Enzymology, 2012, 508, 211-228.

CITATION REPORT

CITATION REPORT

#	Article	IF	CITATIONS
38	Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. Journal of Controlled Release, 2012, 161, 804-812.	4.8	54
39	Cardiac PET-CT and CT Angiography. Current Cardiovascular Imaging Reports, 2013, 6, 191-196.	0.4	0
40	GPR109A and Vascular Inflammation. Current Atherosclerosis Reports, 2013, 15, 325.	2.0	55
41	In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 69.	1.6	55
42	VCAMâ€ <scp>1</scp> â€ŧargeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice. Contrast Media and Molecular Imaging, 2013, 8, 27-39.	0.4	64
43	Technologies: preclinical imaging for drug development. Drug Discovery Today: Technologies, 2013, 10, e343-e350.	4.0	24
44	Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases. Current Cardiovascular Imaging Reports, 2013, 6, 45-54.	0.4	6
45	MR Imaging of the Arterial Vessel Wall: Molecular Imaging from Bench to Bedside. Radiology, 2013, 269, 34-51.	3.6	42
46	Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-11.	1.9	44
47	Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions. International Journal of Nanomedicine, 2014, 9, 4211.	3.3	11
48	Anti-inflammatory mediators for molecular imaging of atherosclerosis. European Journal of Nanomedicine, 2014, 6, .	0.6	0
49	Imaging Atherosclerotic Plaque Inflammation via Folate Receptor Targeting Using a Novel <sup>18</sup> F-Folate Radiotracer. Molecular Imaging, 2014, 13, 7290.2013.00074.	0.7	35
50	Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials, 2015, 53, 341-348.	5.7	116
51	Arterial Effects of Canakinumab in PatientsÂWith Atherosclerosis and TypeÂ2ÂDiabetes or Glucose Intolerance. Journal of the American College of Cardiology, 2016, 68, 1769-1780.	1.2	75
52	Imaging Atherosclerosis. Circulation Research, 2016, 118, 750-769.	2.0	215
53	Strong correlation between early stage atherosclerosis and electromechanical coupling of aorta. Nanoscale, 2016, 8, 6975-6980.	2.8	7
54	Imaging the Coronary Artery Plaque: Approaches, Advances, and Challenges. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.4	2
55	Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery. Theranostics, 2018, 8, 6008-6024.	4.6	19

	CITATION R	CITATION REPORT		
#	Article	IF	CITATIONS	
56	Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching. Theranostics, 2018, 8, 3693-3706.	4.6	44	
57	Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research. Molecules, 2019, 24, 2829.	1.7	31	
58	Clinical value of MRI T2-mapping quantitative assessment of carotid plaque. Acta Radiologica, 2020, 61, 1021-1025.	0.5	0	
59	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. Current Atherosclerosis Reports, 2020, 22, 76.	2.0	4	
60	Principles and Techniques of Biochemistry and Molecular Biology. , 2010, , .		70	
61	Glucose Metabolic Trapping in Mouse Arteries: Nonradioactive Assay of Atherosclerotic Plaque Inflammation Applicable to Drug Discovery. PLoS ONE, 2012, 7, e50349.	1.1	8	
62	Advanced Coronary Imaging. Contemporary Cardiology, 2014, , 23-40.	0.0	0	
63	Noninvasive Imaging Biomarkers of Vulnerable Coronary Plaques – a Clinical Update. Journal of Interdisciplinary Medicine, 2019, 4, 136-140.	0.1	1	
64	Radiolabelled probes for imaging of atherosclerotic plaques. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 432-47.	1.0	18	
65	Assessment of an elastin binding molecule for PET imaging of atherosclerotic plaques. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 326-35.	1.0	3	
66	Highly Bright AIE Nanoparticles by Regulating the Substituent of Rhodanine for Precise Early Detection of Atherosclerosis and Drug Screening. Advanced Materials, 2022, 34, e2106994.	11.1	40	
67	Drug discovery and development. , 0, , 709-735.		0	